(2S)-2-[[2-[3-[2-[2-[(2-aminooxyacetyl)amino]ethoxy]ethoxy]propanoyl-methylamino]-3-methylbutanoyl]amino]-N,3-dimethylbutanamide

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (2S)-2-[[2-[3-[2-[2-[(2-aminooxyacetyl)amino]ethoxy]ethoxy]propanoyl-methylamino]-3-methylbutanoyl]amino]-N,3-dimethylbutanamide
• 化学式: C₂₁H₄₁N₅O₇
• 分子量: 475.6
• InChiKey: PAUPWZGTZDXYTM-OYKVQYDMSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.8
• 重原子数：
  33
• 可旋转键数：
  17
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.81
• 拓扑面积：
  161
• 氢给体数：
  4
• 氢受体数：
  8

文献信息

• GLYCOENGINEERED ANTIBODY DRUG CONJUGATES
  申请人：Genzyme Corporation

  公开号：EP3799887A1

  公开（公告）日：2021-04-07

  The current disclosure provides binding polypeptides (e.g., antibodies), and targeting moiety conjugates thereof, comprising a site-specifically engineered glycan linkage within native or engineered glycans of the binding polypeptide. The current disclosure also provides nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides. Methods of using the antigen-binding polypeptides disclosed herein to treat disease are also provided.

  目前公开的内容提供了结合多肽（如抗体）及其靶向分子共轭物，包括结合多肽的本地或工程聚糖内的位点特异性工程聚糖连接。目前公开的内容还提供了编码抗原结合多肽的核酸、重组表达载体以及用于制造这种抗原结合多肽的宿主细胞。还提供了使用本文公开的抗原结合多肽治疗疾病的方法。
• [EN] FC CONTAINING POLYPEPTIDES WITH ALTERED GLYCOSYLATION AND REDUCED EFFECTOR FUNCTION<br/>[FR] POLYPEPTIDES CONTENANT FC AYANT UNE GLYCOSYLATION MODIFIÉE ET UNE FONCTION EFFECTRICE RÉDUITE
  申请人：GENZYME CORP

  公开号：WO2014043361A1

  公开（公告）日：2014-03-20

  Provided are binding polypeptides (e.g., antibodies), and drug conjugates thereof, comprising an Fc domain with an altered glycosylation profile and reduced effector function. In particular embodiment, the Fc domain comprises: an asparagine residue at amino acid position 298, according to EU numbering; and a serine or threonine residue at amino acid position 300, according to EU numbering. Also provided are nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides. Methods of using the antigen-binding polypeptides disclosed herein to treat disease are also provided.
• [EN] HYPERGLYCOSYLATED BINDING POLYPEPTIDES<br/>[FR] POLYPEPTIDES DE LIAISON HYPERGLYCOSYLÉS
  申请人：GENZYME CORP

  公开号：WO2014164503A1

  公开（公告）日：2014-10-09

  Provided are binding polypeptides (e.g., antibodies), and effector moiety conjugates thereof, comprising a CH1 domain (e.g., a human IgG1 CH1 domain), wherein the CH1 domain has an engineered N-linked glycosylation site at amino acid position (114), according to Kabat numbering. Also provided are nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides. Methods of using the antigen-binding polypeptides disclosed herein to treat disease are also provided.
• [EN] SITE-SPECIFIC ANTIBODY-DRUG CONJUGATION THROUGH GLYCOENGINEERING<br/>[FR] CONJUGAISON ANTICORPS-MÉDICAMENT SPÉCIFIQUE D'UN SITE PAR GLYCO-INGÉNIERIE
  申请人：GENZYME CORP

  公开号：WO2014164534A2

  公开（公告）日：2014-10-09

  The current disclosure provides binding polypeptides (e.g., antibodies), and effector moiety conjugates thereof (e.g., antibody-drug conjugates or ADCs), comprising a site- specifically engineered drug-glycan linkage within native or engineered glycans of the binding polypetpide. The current disclosure also provides nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides. Methods of using the antigen-binding polypeptides disclosed herein to treat disease are also provided.
• [EN] SITE-SPECIFIC GLYCOENGINEERING OF TARGETING MOIETIES<br/>[FR] MODIFICATION DE LA GLYCO-INGÉNIÉRIE DE FRACTIONS DE CIBLAGE SPÉCIFIQUE À UN SITE
  申请人：GENZYME CORP

  公开号：WO2015143091A1

  公开（公告）日：2015-09-24

  The current disclosure provides binding polypeptides (e.g., antibodies), and targeting moiety conjugates thereof, comprising a site-specifically engineered glycan linkage within native or engineered glycans of the binding polypetpide. The current disclosure also provides nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides. Methods of using the antigen-binding polypeptides disclosed herein to treat disease are also provided.